Key clinical point: A substantial proportion of oncology hospitalizations for patients treated with immune checkpoint inhibitors were for immune-related toxicities.
Major finding: Patients treated with combination checkpoint inhibitor therapy (odds ratio, 6.8), in addition to patients aged 65 years and over (odds ratio, 5.4), were more likely to be hospitalized for immune-related toxicities.
Study details: A retrospective analysis of 100 hospitalized patients who had at any point received checkpoint inhibitor therapy.
Disclosures: Financial support was provided by Jarushka Naidoo. The authors reported financial affiliations with AstraZeneca, Bristol-Myers Squibb, Compugen, Genentech, GlaxoSmithKline, Exelixis, MedImmune, and several others.
Balaji A et al. J Oncol Pract. 2019 Aug 6. doi: 10.1200/JOP.18.00703.
Must Reads in Head & Neck Cancers
Monalizumab + cetuximab is active in advanced SCC of the head and neck, Cohen R et al. SITC 2018, Abstract 051
Overall survival lower with cetuximab in oropharyngeal cancer, Mehanna H et al. ESMO 2018, Abstract LBA9_PR